Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Pre-Tax Income
Apontis Pharma AG
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Pre-Tax Income
-€14.8m
|
CAGR 3-Years
-116%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Pre-Tax Income
-$39.3m
|
CAGR 3-Years
27%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Pre-Tax Income
-€209m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Merck KGaA
XETRA:MRK
|
Pre-Tax Income
€3.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
9%
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Pre-Tax Income
€141.8m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Pre-Tax Income
€21.9m
|
CAGR 3-Years
16%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Pre-Tax Income?
Pre-Tax Income
-14.8m
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Pre-Tax Income amounts to -14.8m EUR.
What is Apontis Pharma AG's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 3Y
-116%
The average annual Pre-Tax Income growth rates for Apontis Pharma AG have been -116% over the past three years .
You don't have any saved screeners yet